As transplant vasculopathy is a kind of allograft rejection, there is a need to investigate the effect of ERCs on the treatment of it.
Thus, the objective of this study was to determine whether the expression of B7-H1 on ERCs can be upregulated by the stimulation of IFN-[gamma] and to determine the role of ERC-expressing B7-H1 in preventing transplant vasculopathy in aorta allografts by using neutralizing anti-B7-H1 monoclonal antibody (mAb).
B7-H1 Is Required for ERCs to Alleviate Transplant Vasculopathy. The typical character of transplant vasculopathy is shown by the diffused concentric intimal expansion of the arteries in grafts.
The results may suggest that ERCs can reduce the severity of transplant vasculopathy, and the higher B7-H1 expression, the stronger reduction effect of ERCs was observed.
Chronic rejection is a major factor affecting long-term survival of the transplanted organs, and the transplant vasculopathy is the typical manifestation.
On the basis of previous studies of ERCs, through upregulating B7-H1 by IFN-[gamma] and neutralization of B7-H1 by anti-B7-H1 mAb, the present study has demonstrated that B7-H1 plays a critical role in enhancing the immunosuppressive effects of ERCs both in vitro coculture cell proliferation and in vivo transplant vasculopathy. We have also demonstrated that ERCs attenuated the pathological changes in transplant vasculopathy, which was further alleviated by the IFN-[gamma]-pretreated ERCs.
The key point of alleviating the severity of transplant vasculopathy is to regulate these immune cells and antibodies.
In conclusion, ERCs can prevent the transplant vasculopathy as the intimal growth of transplanted aorta is inhibited.